Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent
Executive Summary
Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.
You may also be interested in...
Bristol/FTC Settlement Brings PTO Standards Into Spotlight
The Federal Trade Commission's antitrust settlement with Bristol-Myers Squibb may bring Patent & Trademark Office standards for pharmaceutical patents into the spotlight
Bristol/FTC Settlement Brings PTO Standards Into Spotlight
The Federal Trade Commission's antitrust settlement with Bristol-Myers Squibb may bring Patent & Trademark Office standards for pharmaceutical patents into the spotlight
APP Accounts For 1% Of Premier Drug Spend: Response To Times Article
American Pharmaceutical Partners accounts for 1% of drugs purchased by Premier, the company said